Endovascular Engineering Secures $80M Series C to Scale Thrombectomy Platform for Stroke Care

Endovascular Engineering is one of those names that sounds clinical until you realize they are in the business of pulling life back from the brink. Blood clots are quiet, efficient, and deadly. Endovascular Engineering, Inc. is building machines that don’t ask politely, they go in and take the problem out. That is the game.

Now the market just leaned in. An $80M Series C, oversubscribed, led by Gilde Healthcare and Norwest, with Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, M&L Healthcare Investments, returning strategic backers, and a new global strategic investor stepping into the room. When that many serious players crowd the cap table, it is not curiosity. It is conviction with a check attached.

Dan Rose and Scott Baron deserve their moment here. CEO and CTO steering a company that is no longer asking for permission to exist. They are building around the Hēlo Thrombectomy Platform, a system designed to go after pulmonary embolisms through peripheral veins. No theatrics, just precision where it counts. If you understand the stakes of VTE, you understand why that matters. Speed, access, outcomes. The trifecta that separates tools from standards.

There is a sequence to how this came together. A $42M Series B not long ago, also oversubscribed, now followed by another round that doubles down. That is not luck. That is execution stacking on execution. Clinical progress through the ENGULF pivotal trial. FDA clearance landing in late 2025. Then capital shows up right on time, like it read the chart and liked the trajectory.

And let’s not ignore the subtext. Commercial stage. Not theory, not someday. Right now. The money is earmarked to scale the commercial engine, build out operations, and keep pushing R&D forward. Translation for anyone keeping score. They are done proving the idea. Now they are proving the market.

There is a certain weight to the name Hēlo. Sounds light, almost effortless. But what it represents is anything but. It is engineering meeting urgency, where milliseconds matter and outcomes are binary. In a space where hesitation costs lives, Endovascular Engineering is designing systems that move with intent.

Congratulations again to Dan Rose, Scott Baron, and the entire Endovascular Engineering team. And credit where it is due to Gilde Healthcare, Norwest, and the full syndicate for recognizing that this is not just another device story. This is what happens when capital meets clarity in a category that does not tolerate mediocrity.